US 11,878,014 B2
Ketamine or dextromethorphan formulations and methods of use
Scott Pollard, Cody, WY (US); Patrick Marshalek, Morgantown, WV (US); and Rae Matsumoto, Stockton, CA (US)
Assigned to West Virginia University, Morgantown, WV (US)
Filed by West Virginia University, Morgantown, WV (US)
Filed on Sep. 28, 2021, as Appl. No. 17/449,196.
Application 17/449,196 is a continuation of application No. 14/644,608, filed on Mar. 11, 2015, granted, now 11,207,316.
Claims priority of provisional application 62/005,326, filed on May 30, 2014.
Prior Publication US 2022/0008412 A1, Jan. 13, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/485 (2006.01); A61K 31/135 (2006.01)
CPC A61K 31/485 (2013.01) [A61K 31/135 (2013.01)] 10 Claims
OG exemplary drawing
 
1. A pharmaceutically acceptable composition comprising:
an effective amount of ketamine or dextromethorphan, or both ketamine and dextromethorphan, wherein said ketamine or said dextromethorphan, or both are distributed within a pharmaceutically acceptable vehicle, wherein said vehicle is capable of being placed in contact with a mucosal membrane of a patient, and wherein said pharmaceutically acceptable vehicle is a device having a mucoadhesive layer containing said ketamine buffered to a pH of between about 4.0 and 7.0, and a non-adhesive backing layer buffered to a pH of between 4.0 and 6.0 wherein the pH of said mucoadhesive layer and said pH of said non-adhesive backing layer are different, wherein said mucoadhesive layer and said non-adhesive backing layer comprise different combinations of polymers but each of said mucoadhesive layer and said non-adhesive backing layer comprise at least one water-erodible polymer wherein said water-erodible polymer is one selected from the group consisting of a cellulosic polymer, an olefinic polymer, a polyether, and a polyalcohol.